The Deane F. Johnson Alzheimer’s Research Foundation’s mission is to fund research focused on finding a prevention and a cure to Alzheimer’s disease. The Foundation strives to identify and remove critical bottlenecks that impede research, while also increasing public awareness of the tragedies caused by the devastatingly degenerative nature of the disease.

The Scope of the Disease

Alzheimer’s disease is rapidly becoming a public health emergency. Without the discovery of new treatments, the number of victims worldwide will grow from 35.6 million in 2010, to 65.7 million in 2030, and to 115.4 million by 2050. These numbers will result in tremendous untold suffering for individuals and families and intolerable expenses for countries and societies. In the U.S. alone, unless methods of prevention are discovered, there will be 1 million new cases annually by 2050 and we will spend $20 trillion on Alzheimer’s between now and 2050.

The Critical Need

New drugs with great potential to treat neurological diseases like Alzheimer’s are rapidly emerging from neuroscience laboratories. Scientists know enough about the basic mechanisms of neurological disease—Alzheimer’s, Parkinson’s, ALS, multiple sclerosis, and epilepsy—to propose specific therapeutic interventions that could stop the cascade of events leading to brain disorders. There is evidence that promising therapies are working in laboratory models and in animals suffering from conditions similar to those of humans. It is essential that these drugs and therapies be tested in persons with the diseases through clinical trials to establish how well they work and if they are safe for humans.

There are two key challenges to more rapid discovery: getting sufficient people to enroll in the clinical trials and supporting these patients through the full regime of testing.

Case Study in Commitment

In 2004, with support from The Deane F. Johnson Alzheimer’s Research Foundation, Kate Edelman Johnson partnered with Dr. Jeffrey Cummings (named #3 in the world for Alzheimer’s research) to establish The Deane F. Johnson Center for Neurotherapeutics at UCLA. The Center is now a nationally respected focal point of clinical trials related to neurological diseases, especially Alzheimer’s and Parkinson’s disease, multiple sclerosis, epilepsy, and stroke.

Fueled by support from the Foundation, the Center is addressing the bottlenecks of clinical trials by developing innovative outreach and enrollment strategies like the Deane Team, a mobile van to transport patients from underserved neighborhoods to be able to participate in the clinical trials, and thereby benefiting from cutting-edge advances in drug therapy. We have created a welcoming, supportive, and efficient environment for the patients and scientists to regularly meet for testing and analysis of conditions.

Since establishing the Center, The Deane F. Johnson Alzheimer’s Research Foundation has mobilized sufficient support to enable Dr. Jeffrey Cummings and his research group to conduct well over 50 clinical trials about Alzheimer’s.

Current Priorities

We have made significant advancements, but there is still much more to accomplish. Today, The Deane F. Johnson Alzheimer’s Research Foundation is reaching out to friends, foundations, and corporations to contribute towards our goal of raising $2.5 million in order to:

  • Develop additional outreach and recruitment strategies to attract more patients to clinical trials. The Center at UCLA is only at 60% capacity and must get to 100%. Support will expand personnel to coordinate outreach, enable us to broaden partnerships with a wide range of community organizations, and heighten public awareness of key clinical trials undenrvay that they can become a part of.
  • Support Alzheimer’s patients and families during their participation in the clinical trials through wider implementation of the Deane’s Team mobile van and other methods.
  • Support the team of scientists under Dr. Jeffrey Cummings’ direction to conduct the backlog of clinical trials.
  • Expand the number of new treatments that can be assessed simultaneously and thus, accelerate the identification of effective new drug interventions.

We Need Your Support

We invite you to join us in support of this important work. Please make a contribution to finding the prevention and the cure Alzheimer’s disease. Through partnering together, we can make a profound difference.